Amplification of the proto-oncogene HER2, a receptor tyrosine kinase (RTK) from the epidermal EGFR family, was found in roughly 20% of breast cancers, while DM amplification was seen in nearly 30% of HER2-positive tumors. The gene discussed is ERBB2; the disease is breast cancer.